Phase II trial of preoperative chemoradiation plus perioperative SOX chemotherapy in patients with locally advanced gastric cancer

Background and Purpose The ideal treatment strategy of patients with locally advanced gastric adenocarcinoma is unclear. The aim of this study is to evaluate the efficacy and feasibility of preoperative chemoradiation in these patients. Patients and Methods All patients underwent laparoscopic exploration or exploratory laparotomy before chemoradiation. Patients received one cycle of S‐1 and oxalipatin followed by concurrent radiation and chemotherapy, then underwent another cycle of S‐1 and oxalipatin. Surgery was performed 6‐8 weeks after completing radiochemotherapy. The rate of curative gastrectomy and survival were investigated. This trial was registered with ClinicalTrial.gov , number NCT02024217. Results From April 2012 to August 2014, 40 patients were enrolled in the trial, and 36 patients were assessable. The most common hematologic toxic effects were leukopenia (80.6%), neutropenia (69.4%), and thrombocytopenia (50%); the most common nonhematologic toxic effects were anorexia (50%), nausea (22.3%), and vomiting (13.9%). There were no treatment related deaths. A total of 33 patients underwent second exploratory laparotomy after preoperative chemoradiation, and 24 (67%) patients received curative gastrectomy. The rates of pathological complete response (pCR) were 13.9%. The medial survival time (MST) was 30.3 months. Conclusion Preoperative chemoradiation may be an effective treatment strategy among patients with locally advanced gastric adenocarcinoma.